SARS-CoV-2 SPIKE Antibody Levels can Indicate Immuno-Resilience to Re-infection: a Real-World Study
Higher antibody titer levels indicated reduced risk of developing symptomatic or severe COVID-19. Titers of ≥ 2500 U/mL indicated a 62-87% reduced infection risk. The quantitative determination of antibody titers allowed scaling of the correlate of risk to new variants.
Authors
- Stanley Letovsky (ORCID: https://orcid.org/0000-0002-5512-1470)
- Yue Jin (ORCID: https://orcid.org/0000-0002-8112-1466)
- Peter Ramge
- Simon Jochum (ORCID: https://orcid.org/0000-0002-7296-5229)
- Fei Yang (ORCID: https://orcid.org/0000-0003-0533-0482)
- Christopher M. Rank
Institutions
- Roche (Switzerland) (CH)
- Roche (United States) (US)
- LabCorp (United States) (US)
- Roche Pharma AG (Germany) (DE)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2024-12-26
- DOI
- https://doi.org/10.1007/s40121-024-01090-2
- Citations
- 3
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.17